::: 台灣東洋製藥 | TTY Biopharm :::

Phases of Development

Management Strategies:

To better improve the value of drug development, we dedicate ourselves to becoming a biopharmaceutical company that focuses on drug development and international marketing. TTY Biopharm is specialized in the research and development of drugs for cancer, anti-infection, cardiovascular disease, and central nerves. With strict assessment procedures for new products and patent analysis, outstanding development capability of our formulation R&D center, and the long-term established scientific data on clinical trials, we develop ourselves to be the leading drug development company in Taiwan and enter the global market with high-barrier to competition and effective drugs of innovative formulations to become the best partner of the companies that are competitive in drug promotion in the target market. On the other hand, we also cultivate our drug development and marketing strength in the home market to become the best partner of international biotechnology companies in Chinese market.
Along with the trend of internationalization, we cooperate with suitable partners in each target market to march toward the global market. In recent years, we have been dedicated to the development of the international market and the establishment of international partnerships. We also plan to build a EU/FDA certified professional cancer pharmaceutical factory and start the research of the genetic technology in cooperation with the government and academic institutes, so that our drug development and manufacturing capabilities can meet international requirements and keep up with the future mainstream to gradually realize our perspective of “using technology to improve the quality of life and improve the international position of Chinese people in the global life industry”.

Phases of Progress

Since the establishment in 1960, TTY Biopharm has transformed from a generic drug manufacturer and seller to an international enterprise focusing on the development of new formulas with the marketing orientation. Constant innovation and progress not only enable us to survive in the rapidly changing and fiercely competitive market, but also drive us into the international market other than Taiwan. Through the Asia market, we directly face competition from international pharmaceutical companies and explicitly defined roles in the global pharmaceutical market. We hope to become the first new drug developer in Asia and further apply our advantages in drug development and marketing technologies to break through the constraint of the environment. We are committed to making a contribution to special Chinese diseases based on innovative knowledge to improve the international position of Chinese people in the global life industry.

Generic drug company phase

1960	TTY Biopharm Co., Ltd. was established as a traditional generic drug pharmaceutical company that focused on production and sales.
1987	Chungli factory passed the GMP inspection, assuring a high quality drug-manufacturing environment.
1988	Signed technical cooperation agreement with French pharmaceutical company Pierre Fabre, U.S. pharmaceutical company Schering-Plough and Whitehall, a pharmaceutical subsidiary of American Home Products Corporation; advanced TTY Biopharm’s drug manufacturing technology.
1988	Signed a technical cooperation agreement with French pharmaceutical company Pierre Fabre, U.S. pharmaceutical company Schering-Plough and Whitehall, a pharmaceutical subsidiary of American Home Products Corporation, advanced TTY Biopharm’s drug manufacturing technology.
1991	Signed technical cooperation agreement with U.S. pharmaceutical company, Mentholatum and U.S. based Bristol-Myer Squibb.
1991	Signed a technical cooperation agreement with U.S. pharmaceutical company Mentholatum & BMS.
1993	Started business in Shanghai, China and set up a new factory in a joint venture with Shanghai XuDong HaiPu Pharmaceutical Co., Ltd. to develop the Great China market together.
1995	Signed a technical cooperation agreement with Germany-based Knoll AG (now a part of pharmaceutical giant, Abbott).
1996	TTY Biopharm repositioned itself as a brand generic drug pharmaceutical company.

Brand Generic Drug Company Phase

In 1996, TTY Biopharm reformed and repositioned itself as a marketing-oriented company. First, we adopted the strategy of branding generic drugs and began to establish the marketing ability, introducing marketing concepts into sales, R&D and manufacturing, an approach that successfully resulted in tremendous increases in margin with a concurrent decrease in expenditures. More cash became available to be channeled into a longer-term research and development.

1997	Signed a technical agreement with Taiwan Liposome Co. to jointly develop liposomal technology, entering the new field of nanotechnology.
1998	Obtained approval for Lipo-Dox as a liposomal injection drug, becoming the third pharmaceutical company in the world to posses Liposomal Doxorubicin manufacturing technology.
1998	Successfully developed Regrow, long acting cough suppressant, in the area of sustained-release products and received the first license for long acting cough suppressant in Taiwan.
1999	Collaborated with Taiwan Liposome Co. to develop and apply for the new generation liposome technology.

Marketing Oriented New Drug Development Phase

In 2000, TTY Biopharma repositioned itself as a marketing-oriented pharmaceutical development company, expecting to be able to perform extensive new drug research between 2006 and 2010. We determined to accumulate intellectual capitals, cultivate the ability of innovation, improve formulas, comply with regulations and clinical trial stipulations, as well as create high barriers to competition in drug manufacturing or formulas. These approaches allowed TTY Biopharm to strive for new formulas and indications.
Currently, we focus on the development a professional anti-cancer drug pharmaceutical company and put emphasis on certain diseases for being the leading brand in that area.

2000	Established the first professional anti-cancer drug plant in Taiwan, and founded TOT (TTY Oncology Team) in the same year. A GMP certified plant and an anti-cancer drug plant was approved in Shanghai for providing medical services for Chinese people.
	Department of Health approved the first domestically developed, orally delivered anti-cancer drug UFUR, making treatments more convenient to patients.
	Filed for Thado patent to be used in hepatoma treatment, providing a new option for patients.
2001	Received approved for a new indication of Lipo-Dox, liposomal injection, allowing a better treatment quality for ovarian cancer patients.
	IPO in Taiwan OTC biotechnology listing.
	Received approval for launching new anti-cancer drugs, Thado, Asadin and Oxalip, creating more options for treatments of hepotoma, leukemia, and colorectal cancer.
2003	TTY Biopharm dedicated in cultivating intelligence, talents, processes, innovations, and relationship structures and commissioned a German consulting company to commence strategy-implementation reforms and strengthen internationalization abilities. Received approval for launching Lacoxa SR, improving the convenience for hip arthritis, and rheumatoid arthritis patients. Established a patent on the new indication for Thalidomide in China. Established a patent on the method for manufacturing Oxaliplatin, injection sterilization product in Taiwan.
2004	Received approved for a new indication for Lipo-Dox, liposomal injection, preventing breast cancer patient form heart diseases. Approval for a new indication fro UFUR, adding a new treatment option for non-small cell carcinoma patients.
2005	Received approval for launching Morpride, Anazo, and Epicin.
2006	Received approval for launching Gemmis,Tyxan, and Ribarin.